Eloxx Pharmaceuticals Stock Net Income
Eloxx Pharmaceuticals fundamentals help investors to digest information that contributes to Eloxx Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Eloxx Pink Sheet. The fundamental analysis module provides a way to measure Eloxx Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Eloxx Pharmaceuticals pink sheet.
Eloxx |
Eloxx Pharmaceuticals Company Net Income Analysis
Eloxx Pharmaceuticals' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Eloxx Pharmaceuticals Net Income | (36.06 M) |
Most of Eloxx Pharmaceuticals' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Eloxx Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
CompetitionBased on the recorded statements, Eloxx Pharmaceuticals reported net income of (36.06 Million). This is 110.57% lower than that of the Pharmaceuticals sector and 151.49% lower than that of the Health Care industry. The net income for all United States stocks is 106.32% higher than that of the company.
Eloxx Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Eloxx Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Eloxx Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Eloxx Pharmaceuticals by comparing valuation metrics of similar companies.Eloxx Pharmaceuticals is currently under evaluation in net income category among its peers.
Eloxx Fundamentals
| Return On Equity | -6.15 | ||||
| Return On Asset | -0.73 | ||||
| Current Valuation | 30.28 M | ||||
| Shares Outstanding | 2.75 M | ||||
| Shares Owned By Insiders | 0.59 % | ||||
| Shares Owned By Institutions | 37.06 % | ||||
| Number Of Shares Shorted | 21.48 K | ||||
| Price To Earning | (7.94) X | ||||
| Price To Book | 6.31 X | ||||
| EBITDA | (34.42 M) | ||||
| Net Income | (36.06 M) | ||||
| Cash And Equivalents | 30.05 M | ||||
| Cash Per Share | 0.35 X | ||||
| Total Debt | 13.38 M | ||||
| Current Ratio | 1.62 X | ||||
| Book Value Per Share | (7.46) X | ||||
| Cash Flow From Operations | (31.84 M) | ||||
| Short Ratio | 0.20 X | ||||
| Earnings Per Share | (12.93) X | ||||
| Target Price | 55.0 | ||||
| Number Of Employees | 18 | ||||
| Beta | 2.68 | ||||
| Market Capitalization | 14.86 M | ||||
| Total Asset | 21.12 M | ||||
| Retained Earnings | (274.39 M) | ||||
| Working Capital | (2.96 M) | ||||
| Current Asset | 3.84 M | ||||
| Current Liabilities | 840.05 K | ||||
| Z Score | -23.07 | ||||
| Net Asset | 21.12 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Other Consideration for investing in Eloxx Pink Sheet
If you are still planning to invest in Eloxx Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eloxx Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |